Projet TrainCKDis (Horizon 2020, appel à projets 2019)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : SIGNED

Chronic kidney disease (CKD) is recognized as an increasing global health problem. It currently affects 10-15% of the worldwide population, is associated with impaired quality of life and reduced life expectancy, and represents a significant burden for health care budgets. CKD is characterized by the progressive decline of renal function. Little is known about the mechanisms underlying this progression and the genetic factors that predispose patients to different rate of progression. Even worse, there is no reliable biomarkers capable to identify patients at risk of fast progression and treatments able to halt CKD progression. Understanding the physiopathology of CKD is therefore a prerequisite for the development of efficient preventive strategies and diagnostic tools. With this goal in mind, TrainCKDis will provide an innovative, multidisciplinary, and intersectoral training programme, able to prepare top-level young scientists to develop creative solutions for CKD. The proposed 15 research projects will address key challenges: i) the identification of genetic and epigenetic modifiers that predispose patients to CKD progression, ii) the identification of pathways and biomarkers for monitoring CKD progression and iii) the identification of novel therapeutic targets to improve the limited treatments for CKD. TrainCKDis gathers top European laboratories, companies, hospitals, and associations involved in the treatment of CKD. Early Stage Researchers (ESRs) will thus benefit from an outstanding interdisciplinary platform integrating nephrology, epidemiology, genetics, cell biology, high-throughput screening, system biology, and metabolomics experts, as well as experimental animal models and unique human biobanks. Moreover, ESRs will be trained in disseminating results through modern channels of communication. Finally, TrainCKDis will provide ESRs with intersectoral and transferable training for efficient career development in both the academic and private sectors.

Mots clés : nephrology, chronic kidney disease  ckd, modifiers genes, epigenetics, biomarkers, therapeutic targets, metabolomics, transcriptomics, system biology, hnf1b, tgf a, hif 1f, uromodulin, angii

Participants :
- Université Paris Cité (France) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 549604.08 €
- Institut national de la santé et de la recherche médicale (France) — Partner, beneficiary, Recherche, subvention : 549604.08 €
- AstraZeneca (Sweden) (Suède) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 281982.96 €
- Leiden University Medical Center (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 265619.88 €
- Charité - Universitätsmedizin Berlin (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 505576.8 €
- University of Freiburg (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 252788.4 €
- European Academy of Bolzano (Italie) — Partner, beneficiary, Recherche, subvention : 261499.68 €
- Mario Negri Institute for Pharmacological Research (Italie) — Partner, beneficiary, Recherche, subvention : 522999.36 €
- University of Zurich (Suisse) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 562553.28 €
- Genomescan b.v. (Pays-Bas) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 265619.88 €